Steelers Announce Inaugural Charity Walk to Benefit The Chuck Noll Foundation for Brain Injury Research

0
1188

Joe Greene and Garrett Webster to Serve as Honorary Co-Chairs

                                                

PITTSBURGH – The Steelers announced they will hold the inaugural Steelers Charity Walk to benefit The Chuck Noll Foundation for Brain Injury Research at Saint Vincent College on Saturday, July 29.

 

The honorary co-chairs for the walk will be former Steeler and Pro Football Hall of Famer, Joe Greene, and Garrett Webster, son of former Steeler and Pro Football Hall of Famer, Mike Webster.

 

Participants will hear Greene reflect on his memories of playing for Coach Noll at 8:30 a.m. at Chuck Noll Field. The walk will begin at 9 a.m. and will follow the Winnie Palmer Nature Trail on the Saint Vincent campus. After the walk, participants will be able to watch the Steelers’ morning practice.

 

Registration is available at www.steelers.com/charitywalk. The cost is $25 per registration and includes a commemorative t-shirt.

The Steelers launched The Chuck Noll Foundation for Brain Injury Research in November of 2016 to support continued research and education regarding brain injuries and treatment of sports-related concussions. The Foundation will fund research that it believes is the most promising in the area of sports-related concussions and related conditions. To help best evaluate which research programs to fund, some of the most renowned neurosurgeons in the country will serve on a national medical advisory panel.

Under Noll’s leadership during his 23-year coaching career, the Steelers became the first team in NFL history to win four Super Bowls. Noll’s commitment to the well-being of his players ultimately led to the development of the ImPACT test (Immediate Post-Concussion Assessment and Cognitive Testing) used by NFL team doctors since 2007, and now internationally used to help monitor concussions for athletes at all levels. The FDA recently recognized ImPACT and ImPACT Pediatric as safe and effective, and are the only FDA-approved tests to assess cognitive function for suspected brain injury in patients ages 5-to-60. To date, more than 12-million athletes and patients have been baselined with these tests.